

CILOZEN-100 TABLETS

Cilostazol I.P. 100 mg

"Improving Circulation Reducing Claudication Enhancing Mobility"

Marketed by: Human Orthocare
A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com



Product Overview

Composition (per tablet):

 **Cilostazol I.P. – 100 mg**

Key Features:

- Phosphodiesterase III (PDE-3) inhibitor
- Vasodilator & antiplatelet action
- Increases blood flow to limbs by reducing vascular resistance
- Improves walking distance in patients with intermittent claudication

Cilozen-100 represents advanced pharmaceutical innovation in peripheral vascular disease management, combining dual therapeutic mechanisms for optimal patient outcomes.



Mechanism of Action

01

PDE-3 Inhibition

Cilostazol inhibits phosphodiesterase III, leading to increased cyclic adenosine monophosphate (cAMP) levels in vascular smooth muscle and platelets

03

Antiplatelet Action

Inhibits platelet aggregation, reducing the risk of thrombosis and improving blood flow through narrowed arteries

02

Vasodilation

Elevated cAMP causes smooth muscle relaxation and vasodilation, improving peripheral circulation and reducing vascular resistance

04

Enhanced Oxygenation

Improved tissue oxygenation and enhanced mobility result in increased walking distance and reduced leg pain in peripheral vascular disease

✓ **Clinical Result:** Improved walking distance & reduced leg pain in peripheral vascular disease patients



Clinical Indications

Cilozen-100 is specifically recommended for comprehensive management of peripheral vascular conditions:

Intermittent Claudication

Primary indication for intermittent claudication due to peripheral arterial disease (PAD), significantly improving walking tolerance

Secondary Prevention

Secondary prevention of vascular events in PAD patients, reducing long-term cardiovascular complications


Arterial Insufficiency

Adjunct therapy in chronic arterial insufficiency, enhancing overall vascular function and patient mobility

Diabetic Complications

Supportive treatment in diabetic peripheral vascular disease, addressing circulation complications in diabetic patients

Clinical Advantages



Key Benefits of Cilozen-100:


- Enhanced Walking Distance**
Improves pain-free walking distance significantly, allowing patients to maintain active lifestyles
- Pain Reduction**
Reduces leg pain & cramping due to poor circulation, improving daily comfort and mobility
- Dual Therapeutic Action**
Combines vasodilation and antiplatelet effects for comprehensive vascular protection
- Quality of Life**
Significantly improves quality of life in PAD patients through enhanced mobility and reduced symptoms
- Proven Efficacy**
Oral therapy with clinically proven efficacy and established tolerability profile

Comparison with Other Therapies

Cilozen-100 demonstrates superior therapeutic advantages compared to alternative treatments:

Parameter	Cilozen-100 (Cilostazol)	Pentoxifylline	Antiplatelets Alone
Vasodilation	✔ Strong	⚠ Mild	✗ None
Antiplatelet Effect	✔ Yes	✗ No	✔ Yes
Walking Distance Improvement	✔ Significant	⚠ Limited	✗ Absent
Quality of Life	✔ High	⚠ Moderate	⚠ Supportive only

Dosage & Administration



i Recommended Dosage:

100 mg tablet orally, twice daily

Best taken 30 minutes before or 2 hours after meals to improve absorption

Initial Response

Clinical benefit requires 2–4 weeks of consistent therapy

1

Continuation Criteria

Therapy should be continued only if improvement is observed within 3 months

2

Maximum Effect

Peak therapeutic effect achieved within 12 weeks of treatment

3

Safety & Tolerability

Generally Well-Tolerated

Possible Side Effects:

- Headache, dizziness, palpitations
- Diarrhoea, abdominal pain
- Rare: arrhythmias, thrombocytopenia



Contraindications:

- Heart failure (any severity)
- Recent myocardial infarction or stroke
- Severe hepatic or renal impairment
- Hypersensitivity to cilostazol

Comprehensive safety monitoring ensures optimal patient outcomes whilst maintaining therapeutic efficacy across diverse patient populations.



Why Prescribe Cilozen-100?



Proven Efficacy

Highly effective in treating intermittent claudication due to peripheral arterial disease



Dual Mechanism

Unique combination of vasodilator and antiplatelet actions for comprehensive treatment



Enhanced Mobility

Significantly improves patient mobility and walking distance capacity



Life Quality

Enhances quality of life in vascular-compromised patients through symptom relief



Trusted Quality

Backed by the trusted quality and reliability of Human Orthocare



**Human
Ortho Care**

A SUBSIDIARY OF HUMAN BIOLIFE INDIA PVT. LTD.

Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:



www.humanorthocare.com